SCHEMBL7514741

SCHEMBL7514741

Cc1ccc(S(=O)(=O)n2c(/C=C3/SC(=O)NC3=O)cc3cc(-c4nc5cc(Cl)c(Cl)cc5[nH]4)ccc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.38
PIM1 P11309 1/20 0.36
HPGD P15428 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 1/20 0.35
GLS O94925 1/20 0.35
GLS2 Q9UI32 1/20 0.35
IGF1R P08069 3/20 0.35
INSR P06213 1/20 0.35
MAPT P10636 1/20 0.35
HSPD1 P10809 1/20 0.35
PTPN2 P17706 1/20 0.35
PTPN5 P54829 1/20 0.35
HSPE1 P61604 1/20 0.35
RHEB Q15382 2/20 0.34
MGAM O43451 1/20 0.34
GAA P10253 1/20 0.34
SI P14410 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7514753 1.00 PTPN1 (0.38) PTPN1PIM1HPGDPIM2MEN1
SCHEMBL7518342 0.85 HPGD (0.41) PTPN1PIM1HPGDPIM2MEN1
SCHEMBL7518345 0.85 HPGD (0.41) PTPN1PIM1HPGDPIM2MEN1
SCHEMBL7512632 0.78 PIM1 (0.49) PTPN1PIM1HPGDPIM2MEN1
SCHEMBL7516823 0.75 IGF1R (0.56) PIM1HPGDPIM2IGF1RINSR
SCHEMBL7516825 0.75 IGF1R (0.56) PIM1HPGDPIM2IGF1RINSR
SCHEMBL7515782 0.75 IGF1R (0.54) PIM1HPGDPIM2IGF1RINSR
SCHEMBL7515778 0.75 IGF1R (0.54) PIM1HPGDPIM2IGF1RINSR
SCHEMBL7515519 0.73 IGF1R (0.44) PIM1HPGDPIM2GLSGLS2
SCHEMBL7515515 0.73 IGF1R (0.44) PIM1HPGDPIM2GLSGLS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 PTPN1 2464/4885PIM1 1545/4885HPGD 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.